| |  Online-Ressource |
|---|
| Verfasst von: | Metzner, Thomas [VerfasserIn]  |
|---|
| | Leitner, Deborah R. [VerfasserIn] |
|---|
| | Mellitzer, Karin [VerfasserIn] |
|---|
| | Beck, Andrea [VerfasserIn] |
|---|
| | Sourij, Harald [VerfasserIn] |
|---|
| | Stojakovic, Tatjana [VerfasserIn] |
|---|
| | Reishofer, Gernot [VerfasserIn] |
|---|
| | März, Winfried [VerfasserIn] |
|---|
| | Landmesser, Ulf [VerfasserIn] |
|---|
| | Scharnagl, Hubert [VerfasserIn] |
|---|
| | Toplak, Hermann [VerfasserIn] |
|---|
| | Silbernagel, Günther [VerfasserIn] |
|---|
| Titel: | Effects of alirocumab on triglyceride metabolism |
|---|
| Titelzusatz: | a fat-tolerance test and nuclear magnetic resonance spectroscopy study |
|---|
| Verf.angabe: | Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak and Günther Silbernagel |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 17 January 2022 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 16.05.2023 |
|---|
| Titel Quelle: | Enthalten in: Biomedicines |
|---|
| Ort Quelle: | Basel : MDPI, 2013 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 10(2022), 1, Artikel-ID 193, Seite 1-13 |
|---|
| ISSN Quelle: | 2227-9059 |
|---|
| Abstract: | Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. Methods: A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were two visits at the study site: the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. Fat-tolerance tests, nuclear magnetic resonance spectroscopy, and enzyme-linked immunosorbent assays were performed to analyze lipid metabolism. Results: A total of 21 participants underwent the first and second investigation. Among these, two participants only received alirocumab twice and 19 patients completed the trial per protocol. All of them had atherosclerotic vascular disease. There was no significant effect of alirocumab treatment on fasting triglycerides, post-prandial triglycerides, or lipoprotein-lipase regulating proteins. Total, large, and small LDL particle concentrations decreased, while the HDL particle concentration increased (all p < 0.001). Mean total circulating PCSK9 markedly increased in response to alirocumab treatment (p < 0.001). Whereas PCSK9 increased more than three-fold in all 19 compliant patients, it remained unchanged in those two patients with two injections only. Conclusion: Significant effects of alirocumab on triglyceride metabolism were not detectable in the ALIROCKS trial. The total circulating PCSK9 concentration might be a useful biomarker to differentiate non-adherence from non-response to PCSK9 antibodies. |
|---|
| DOI: | doi:10.3390/biomedicines10010193 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/biomedicines10010193 |
|---|
| | kostenfrei: Volltext: https://www.mdpi.com/2227-9059/10/1/193 |
|---|
| | DOI: https://doi.org/10.3390/biomedicines10010193 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | alirocumab |
|---|
| | fat-tolerance test |
|---|
| | lipids |
|---|
| | nuclear magnetic resonance spectroscopy |
|---|
| | PCSK9 |
|---|
| K10plus-PPN: | 1845499387 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Effects of alirocumab on triglyceride metabolism / Metzner, Thomas [VerfasserIn]; 17 January 2022 (Online-Ressource)
